Stock QBIO Q BIOMED INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Q BioMed Inc. Other OTC

Equities

QBIO

US74736N1054

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Q BioMed Inc. Provides Update to Shareholders
PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
PR
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
Q BIOMED PROVIDES SHAREHOLDER UPDATE
PR
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
PR
Q BioMed Inc. Provides Update to Shareholders
PR
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)
PU
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
PR
Q BIOMED INC. : Unregistered Sale of Equity Securities (form 8-K)
AQ
Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets
PR
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
AQ
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer
PR
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market
PR
Q BIOMED INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Q BioMed Outlines Strategic Direction for 2022
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QBIO Stock
  4. QBIO Stock
  5. News Q BioMed Inc.
  6. Press Releases